198 related articles for article (PubMed ID: 20814199)
1. Peroxisome proliferator-activated receptor-γ agonist rosiglitazone prevents albuminuria but not glomerulosclerosis in experimental diabetes.
Setti G; Hayward A; Dessapt C; Barone F; Buckingham R; White K; Bilous R; Hiroshi K; Gruden G; Viberti G; Gnudi L
Am J Nephrol; 2010; 32(5):393-402. PubMed ID: 20814199
[TBL] [Abstract][Full Text] [Related]
2. The combination of sirolimus and rosiglitazone produces a renoprotective effect on diabetic kidney disease in rats.
Flaquer M; Lloberas N; Franquesa M; Torras J; Vidal A; Rosa JL; Herrero-Fresneda I; Grinyó JM; Cruzado JM
Life Sci; 2010 Jul; 87(5-6):147-53. PubMed ID: 20600147
[TBL] [Abstract][Full Text] [Related]
3. PPAR-alpha and -gamma agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse.
Calkin AC; Giunti S; Jandeleit-Dahm KA; Allen TJ; Cooper ME; Thomas MC
Nephrol Dial Transplant; 2006 Sep; 21(9):2399-405. PubMed ID: 16720596
[TBL] [Abstract][Full Text] [Related]
4. Potential for peroxisome proliferator-activated receptor-gamma agonists in progression: beyond metabolism.
Fogo AB
Curr Opin Nephrol Hypertens; 2008 May; 17(3):282-5. PubMed ID: 18408479
[TBL] [Abstract][Full Text] [Related]
5. Peroxisome proliferator-activated receptor-δ activation ameliorates albuminuria by preventing nephrin loss and restoring podocyte integrity in type 2 diabetes.
Lee EY; Kim GT; Hyun M; Kim S; Seok S; Choi R; Lee MY; Chung CH
Nephrol Dial Transplant; 2012 Nov; 27(11):4069-79. PubMed ID: 22892126
[TBL] [Abstract][Full Text] [Related]
6. Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease.
Yu J; Jin N; Wang G; Zhang F; Mao J; Wang X
Metabolism; 2007 Oct; 56(10):1396-401. PubMed ID: 17884451
[TBL] [Abstract][Full Text] [Related]
7. Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats.
Ko GJ; Kang YS; Han SY; Lee MH; Song HK; Han KH; Kim HK; Han JY; Cha DR
Nephrol Dial Transplant; 2008 Sep; 23(9):2750-60. PubMed ID: 18388116
[TBL] [Abstract][Full Text] [Related]
8. Correction of protein kinase C activity and macrophage migration in peripheral nerve by pioglitazone, peroxisome proliferator activated-gamma-ligand, in insulin-deficient diabetic rats.
Yamagishi S; Ogasawara S; Mizukami H; Yajima N; Wada R; Sugawara A; Yagihashi S
J Neurochem; 2008 Jan; 104(2):491-9. PubMed ID: 17995925
[TBL] [Abstract][Full Text] [Related]
9. Rosiglitazone is effective to improve renal damage in type-1-like diabetic rats.
Huang KC; Cherng YG; Chen LJ; Hsu CT; Cheng JT
Horm Metab Res; 2014 Apr; 46(4):240-4. PubMed ID: 24136780
[TBL] [Abstract][Full Text] [Related]
10. The roles of Kruppel-like factor 6 and peroxisome proliferator-activated receptor-γ in the regulation of macrophage inflammatory protein-3α at early onset of diabetes.
Qi W; Holian J; Tan CY; Kelly DJ; Chen XM; Pollock CA
Int J Biochem Cell Biol; 2011 Mar; 43(3):383-92. PubMed ID: 21109018
[TBL] [Abstract][Full Text] [Related]
11. The low dose combination of fenofibrate and rosiglitazone halts the progression of diabetes-induced experimental nephropathy.
Arora MK; Reddy K; Balakumar P
Eur J Pharmacol; 2010 Jun; 636(1-3):137-44. PubMed ID: 20347778
[TBL] [Abstract][Full Text] [Related]
12. Thiazolidinediones ameliorate diabetic nephropathy via cell cycle-dependent mechanisms.
Okada T; Wada J; Hida K; Eguchi J; Hashimoto I; Baba M; Yasuhara A; Shikata K; Makino H
Diabetes; 2006 Jun; 55(6):1666-77. PubMed ID: 16731829
[TBL] [Abstract][Full Text] [Related]
13. Rosiglitazone prevents advanced glycation end products-induced renal toxicity likely through suppression of plasminogen activator inhibitor-1.
Yu X; Li C; Li X; Cai L
Toxicol Sci; 2007 Apr; 96(2):346-56. PubMed ID: 17264099
[TBL] [Abstract][Full Text] [Related]
14. Huangkui capsule, an extract from Abelmoschus manihot (L.) medic, improves diabetic nephropathy via activating peroxisome proliferator-activated receptor (PPAR)-α/γ and attenuating endoplasmic reticulum stress in rats.
Ge J; Miao JJ; Sun XY; Yu JY
J Ethnopharmacol; 2016 Aug; 189():238-49. PubMed ID: 27224243
[TBL] [Abstract][Full Text] [Related]
15. [Pentosan polysulfate sodium prevents kidney morphological changes and albuminuria in rats with type 1 diabetes].
Mathison Natera Y; Finol HJ; Quero Z; González R; González J
Nefrologia; 2010; 30(6):639-45. PubMed ID: 21113213
[TBL] [Abstract][Full Text] [Related]
16. Transcriptional regulation of nephrin gene by peroxisome proliferator-activated receptor-gamma agonist: molecular mechanism of the antiproteinuric effect of pioglitazone.
Benigni A; Zoja C; Tomasoni S; Campana M; Corna D; Zanchi C; Gagliardini E; Garofano E; Rottoli D; Ito T; Remuzzi G
J Am Soc Nephrol; 2006 Jun; 17(6):1624-32. PubMed ID: 16687628
[TBL] [Abstract][Full Text] [Related]
17. Stretch reduces nephrin expression via an angiotensin II-AT(1)-dependent mechanism in human podocytes: effect of rosiglitazone.
Miceli I; Burt D; Tarabra E; Camussi G; Perin PC; Gruden G
Am J Physiol Renal Physiol; 2010 Feb; 298(2):F381-90. PubMed ID: 19906946
[TBL] [Abstract][Full Text] [Related]
18. Activation of tubular epithelial cells in diabetic nephropathy and the role of the peroxisome proliferator-activated receptor-gamma agonist.
Tang SC; Leung JC; Chan LY; Tsang AW; Lai KN
J Am Soc Nephrol; 2006 Jun; 17(6):1633-43. PubMed ID: 16687627
[TBL] [Abstract][Full Text] [Related]
19. Rosiglitazone, a peroxisome proliferator-activated receptor γ stimulant, abrogates diabetes-evoked hypertension by rectifying abnormalities in vascular reactivity.
El-Bassossy HM; Abo-Warda SM; Fahmy A
Clin Exp Pharmacol Physiol; 2012 Aug; 39(8):643-9. PubMed ID: 22594672
[TBL] [Abstract][Full Text] [Related]
20. Anti-diabetic effects including diabetic nephropathy of anti-osteoporotic trace minerals on diabetic mice.
Maehira F; Ishimine N; Miyagi I; Eguchi Y; Shimada K; Kawaguchi D; Oshiro Y
Nutrition; 2011 Apr; 27(4):488-95. PubMed ID: 20708379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]